The diversity of T-cell co-stimulation in the induction of antitumor immunity

Immunological Reviews

Volumn 170, Issue , 1999, Pages 73-84

  Schlom, Jeffrey ^a   Hodge, James W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR VACCINE;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; LIGAND BINDING; LUNG METASTASIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; VACCINIA VIRUS; VIRUS RECOMBINANT;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; INTERCELLULAR ADHESION MOLECULE-1; LYMPHOCYTE ACTIVATION; NEOPLASMS, EXPERIMENTAL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 0032866605     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01330.x     Document Type: Review

References (64)

1. 1. Fries LF, et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 1996;14:428-434.
2. 2. Tubiana R, et al. Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity. AIDS 1997;11:819-820.
3. 3. Egan MA, et al. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a non-replicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J Infect Dis 1995;171:1623-1627.
4. 4. Belshe RB, et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS 1998;17:2407-2415.
5. 5. Clements-Mann ML, et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. J Infect Dis 1998;177:1230-1246.
6. 6. Graham BS, et al. Vaccination of vaccinia-naïve adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. J Infect Dis 1992;166:244-252.
7. 7. Demkowicz WE Jr, et al. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. J Virol 1996;70:2627-2631.
8. 8. Stienlauf S, et al. Kinetics of formation of neutralizing antibodies against vaccinia virus following re-vaccination. Vaccine 1999;17:201-204.
9. 9. McAneny D, et al. Results of a phase I trial of a recombinant vaccinia virus that expressed carcinoembryonic antigen in patients with advanced colorectal cancer. Ann Surg Oncol 1996;3:495-500.
10. 10. Sanda MG, et al. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen modulated human prostate cancer. Urology 1999;53:260-266.
11. 11. Irvine KJ, Schlom J. Comparison of a CEA-recombinant vaccinia virus, purified CEA, and an anti-idiotype antibody bearing the image of a CEA epitope in the treatment and prevention of CEA-expressing tumors. Vaccine Res 1993;2:79-94.
12. 12. Kass E, et al. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 1999;59:676-683.
13. 13. Bernards R, et al. Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc Natl Acad Sci USA 1987;19:6854-6858.
14. 14. Hodge JW, et al. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 1997;15:759-768.
15. 15. Bei R, et al. Enhanced immune responses and anti-tumor activity by baculovirus recombinant carcinoembryonic antigen (CEA) in mice primed with the recombinant vaccinia CEA. J Immunother Emphasis Tumor Immunol 1994;16:275-282.
16. 16. Corey L, et al. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. J Infect Dis 1998;177:301-309.
17. 17. Marshall JL, et al. Phase I/II trial of Vaccinia-CEA and ALVAC-CEA in patients with advanced CEA-bearing tumors. Meeting Abstract, American Society of Clinical Oncology (ASCO), 35th Annual Meeting, Atlanta, Georgia, May 15-18, 1999.
18. 18. Cole DJ, et al. Phase I study of recombinant CEA vaccinia virus vaccine with post-vaccination CEA peptide challenge. Hum Gene Ther 1996;7:1381-1394.
19. 19. Graham BS, et al. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naïve volunteers primed with gp160-recombinant vaccinia virus. J Infect Dis 1994;170:782-786.
20. 20. Montefiori DC, et al. Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. J Clin Immunol 1992;12:429-439.
21. 21. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination and safety. Proc Natl Acad Sci USA 1996;93:11341-11348.
22. 22. Moss B, et al. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol 1996;397:1-13.
23. 23. Carroll MW, et al. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 1997;15:387-394.
24. 24. Tartaglia J, et al. Canarypox virus-based vaccine: prime boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res Hum Retroviruses 1998;14:S291-S298.
25. 25. Ockenhouse CF, et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 1998;177:1664-1673.
26. + T-cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J Immunol 1991;146:3235-3241.
27. 27. Hodge JW, McLaughlin JP, Abrams S, Shupert WL, Schlom J, Kantor JA. The admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7-I and a recombinant vaccinia virus containing a tumor associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res 1995;55:3598-3603.
28. 28. Kalus RM, et al. The use of combination vaccinia vaccines to enhance antigen-specific T cell immunity via T-cell costimulation. Vaccine 1999;17:893-903.
29. 29. Qin H, Chatterjee SK. Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF. Hum Gene Ther 1996;7:1853-1860.
30. 30. McLaughlin JP, et al. Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long lasting systemic immunity. J Immunother 1997;20:449-459.
31. 31. Dranoff G, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-3543.
32. 32. Hodge JW, et al. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 1994;54:5552-5555.
33. 33. Uzendoski K, et al. Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses. Hum Gene Ther 1997;8:851-860.
34. 34. Lorenz MGO, et al. Induction of antitumor immunity elicited by recombinant vaccinia virus expressing murine leukocyte function associated antigen-3 (LFA-3). Hum Gene Ther 1999;10:623-631.
35. 35. Lorenz MGO, et al. Antitumor immunity elicited by a reeombinant vaccinia virus expressing CD70 (CD27L). Hum Gene Ther 1999;10:1095-1103.
36. 36. Dunussi-Joannopoulos K, et al. Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood 1996;87:2938-2946.
37. 37. Emtage PCR, et al. Enhanced interleukin-2 gene transfer immunotherapy of breast cancer by coexpression of B7-1 and B7-2. J Interferon Cytokine Res 1998;18:927-937.
38. 38. Gajewski TF, et al. Tumor rejection requires a CTLA-4 ligand provided by the host or expressed on the tumor. J Immunol 1996;156:2909-2917.
39. 39. Chen L, et al. Tumor immunogenicity determines the effect of B7-1 costimulation on T cell-mediated tumor immunity. J Exp Med 1994;179:523-532.
40. 40. Schlom J, Hodge JW. Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines. Cancer Res (In press).
41. 41. Wallack MK, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998;187:69-77.
42. 42. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-1736.
43. 43. Greenfield EA, Nguyen KA, Kuchroo VK. CD28/B7-1 costimulation: a review. Crit Rev Immunol 1998;18:389-418.
44. 44. Yang YF, et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res 1997;57:4036-4041.
45. 45. Mokyr MB, et al. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res 1998;58:5301-5304.
46. 46. Wong YW, Williams AF, Kingsmore SF, Seldin MF. Structure, expression, and genetic linkage of the mouse BCM1 (OX45 or Blast 1) antigen. Evidence for genetic duplication giving rise to the BCM1 region on mouse chromosome 1 and the CD2/LFA3 region on mouse chromosome 3. J Exp Med 1990;171:2115-2130.
47. 47. Selvaraj P, Plunkett ML, Dustin M, Sande ME, Shaw S, Springer TA. The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3. Nature 1987;326:400-403.
48. 48. Davis SJ, Van Der Merwe PA. The structure and ligand interactions of CD2: implications for T-cell function. Immunol Today 1996;17:177-187.
49. 49. Altevogt P, Michaelis M, Kyewski B. Identical forms of the CD2 antigen expressed by mouse T and B lymphocytes. Eur J Immunol 1989;19:1509-1512.
50. 50. Yagita H, Okumura K, Nakauchi H. Molecular cloning of the murine homologue of CD2. Homology of the molecule to its human counterpart T11. J Immunol 1989;140:1321.
51. 51. Meuer SC, et al. An alternative pathway of T-cell activation: a functional role for the 50 kd T11 sheep erythrocyte receptor protein. Cell 1984;36:897-906.
52. 52. Guckel B, Berek C, Lutz P, Altevogt V, Schirrmacher V, Kyewski BA. Anti-CD2 antibodies induce T cell unresponsiveness in vivo. J Exp Med 1991;176:1241-1240.
53. 53. Genaro AM, Gonzalo JA, Bosca L, Martinez C. CD2-CD48 interaction prevents apoptosis in murine B lymphocytes by upregulating bcl-2 expression. Eur J Immunol 1994;24:2515-2521.
54. 54. Ayroldi E, Migliorati G, Cannarile L, Moraca R, Delfino DV, Riccardi C. CD2 rescues T cells from T-cell receptor/CD3 apoptosis: a role for the Fas/Fas-L system. Blood 1997;89:3717-3726.
55. 55. Chavin KD, Qin L, Lin J, Kaplan AJ, Bromberg JS. Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival with decreased side effects. Transplantation 1993;55:901-908.
56. 56. Anasetti C, et al. Induction of calcium flux and enhancement of cytolytic activity in natural killer cells by cross-linking of the sheep erythrocyte binding protein (CD2) and the Fc receptor (CD16). J Immunol 1987;139:1772-1779.
57. + killer cell clones by monoclonal antibodies (anti-CD16, anti-CD2, anti-CD3) depends on subclass specificity of target cell IgG-FcR. J Immunol 1987;138:3137-3144.
58. + T cells. J Immunol 1997;158:637-642.
59. 59. Cavallo F, et al. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur J Immunol 1995;25:1154-1162.
60. 60. Wingren AG, et al. T cell activation pathways: B7-1, LFA-3, and ICAM-1 shape unique T-cell profiles. Crit Rev Immunol 1995;15:235-253.
61. 61. Hellstrom KE, et al. Costimulation of T cell mediated tumor immunity: costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. Cancer Chemother Pharmacol 1996;38: S40-S41.
62. 62. Freund YR, et al. Vaccination with recombinant vaccinia vaccine containing the B7-1 costimulatory molecule causes no significant toxicity and enhances cell mediated cytotoxicity. Int J Cancer (In press).
63. 63. von Mehren M, et al. Phase I trial with ALVAC-CEA B7-1 immunization in advanced CEA-expressing adenocarcinomas. Meeting Abstract, American Society of Clinical Oncology (ASCO), 35th Annual Meeting, Atlanta, Georgia, May 15-18, 1999.
64. 64. Lee DS, et al. Preliminary results of ALVAC-CEA-B7-1 phase I vaccine trial in patients with metastatic CEA-expressing tumors. Meeting Abstract, American Society of Clinical Oncology (ASCO), 35th Annual Meeting, Atlanta, Georgia, May 15-18, 1999.